Ann: Appendix 4E-ADO.AX, page-17

If investors do calculate Diasource earnings on an annual basis with 3 additional products just hit markets, one possibly lined up for US market distribution ( see previous posts about the FDA application ) they might have to revisit the current PE value of Anteo which is ridiculously low, as in almost not being represented in current MC.
We are still reeling from an artificially low share price due to vested interest of parties to load up on stock at very low prices.
We are nowhere near fairly valued momentarily.

The coming weeks in Sept/ Oct will, in my opinion, bring a rising PE evaluation into the equation and should double the share price by end of the year.


The expected energy news, with recent hint towards readiness of both Anteo and clients to proceed in yesterday's update, could accelerate price appreciation.